Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the goal of the AIM2CERV trial, which is to evaluate whether or not axalimogene filolisbac can prevent or reduce the risk of cervical cancer recurrence after patients received the initial standard of care. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
What is the Goal of AIM2CERV Trial?
